Long time investor, retired from tech space
United States
Joined July 2020
- Tweets4.2K
- Following314
- Followers1.1K
- Likes1.7K
$GANX Gain Therapeutics has now shown after 360 days none of the patients showed Parkinson’s progression on the gold standard UPDRS scale. World first Parkinson’s modifying drug.
You should sell and move on. This is what Khalid said about the drug today. If anyone knows he knows. If you noticed nothing is moving in the small biotech space.
Roches deal is 5 to 10 years out. They might not even start a safety test for another year. Rexeceract can be helping patients in 2 years with the right big pharma. Isn't that what we all want? No drug has ever returned smell/taste and this one did it on 25% of patients in 90 day
$GANX Gain Therapeutics. This is what their data look against Roches billion dollar drug. Rexaceract shows stable and no progression. Roche maybe slows Parkinson’s?
$GANX First company to stop Parkinson’s progression. Historic data.
$GANX NEWS IS STUNNING
Stock Doesn’t Move…
“In the 12 evaluable participants, MDS-UPDRS motor scores were stable over the 12-month study period with rexaceract, demonstrating no clinically meaningful progression of motor symptoms”
🤯🤯🤯 READ THIS
globenewswire.com/news-relea…
$GANX Gain Therapeutics. Would be nice if they put this out on their social. @GainThera
Watch "This CEO is Fighting Parkinson’s & Other Neuro-Degenerative Diseases. Gene Mack - Gain Therapeutics" on YouTube
youtu.be/exCO7jGwmZE?is=Zn9q…
$GANX Parkinson’s is slow moving well understood disease in terms of the gold standard UPDRS scores. MJ Fox PPMI scale says 5+ points per year in worsening. We had a subgroup improve 6 points. We will be bought before Phase 2. Data excellent and big pharma knows it.
$GANX Gain Therapeutics. Looks like their former CMO started work at Bristol Myers. Let's us know they are aware of Gain and must think highly of his work on GT-02287.
$GANX Gain Therapeutics. Recent interview worth listening to. 270 and 360 day data coming up. Parkinsons patients are not getting worse.
Watch "Parkinson’s Breakthrough? GANX CEO Gene Mack on 9-Month Data, Bial’s Failure & What’s Next" on YouTube
youtu.be/AF6T_MEZ-mQ?is=xecW…
$GANX This is the 90 day data of GT-02287 and we have been told as they finish a year it has been durable and stable. In this data I removed 2 patients out of 14 who did not respond in the first 90 days. They did stay in the 9 month extension study so they may have seen benefits.
$GANX BTIG report confirms that the IND allows company to more aggressively seek a partner to develop the first Parkinson’s Disease modifying drug.
